Docosatetraenoylethanolamide
 | |
| Names | |
|---|---|
| IUPAC name
(7Z,10Z,13Z,16Z)-N-(2-hydroxyethyl)docosa-7,10,13,16-tetraenamide | |
| Other names
DEA | |
| Identifiers | |
150314-35-5  | |
| 3D model (Jmol) | Interactive image |
| ChEMBL | ChEMBL321585  |
| ChemSpider | 4445444 |
| 5445 | |
| PubChem | 5282273 |
| |
| |
| Properties | |
| C24H41NO2 | |
| Molar mass | 375.59 g/mol |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| verify (what is ?) | |
| Infobox references | |
Docosatetraenoylethanolamide (DEA) is an endogenous ethanolamide that has been shown to act on the cannabinoid (CB1) receptor.[1] DEA is similar in structure to anandamide (AEA, a recognized endogenous ligand for the CB1 receptor), containing docosatetraenoic acid in place of arachidonic acid. While DEA has been shown to bind to the CB1 receptor with similar potency and efficacy as AEA, its role as a cannabinergic neurotransmitter is not well understood.
References
- ↑ Hanus, L.; Gopher, A.; Almog, S.; et al. (1993). "Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor". J Med Chem. 36 (20): 3032–3034. doi:10.1021/jm00072a026. PMID 8411021.
This article is issued from Wikipedia - version of the 7/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.